Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Phytochemistry|November 14, 2006
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganicaHuizhen Liu, Kent Gunnertoft Jensen, Linh My Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?J L Gala, S Loric, Y Guiot, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2021
Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen TherapyMark C Markowski, Pedro Isaacsson Velho, Mario A Eisenberger, et al.
Annals of Nuclear Medicine|June 1, 2019
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CTAlexa R Meyer, Michael A Carducci, Samuel R Denmeade, et al.
The Prostate|September 23, 2024
Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case seriesElizabeth U Tran, Eric Royz, Kyra Yamamoto, et al.
American Journal of Clinical Oncology|August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Pageof 23